Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
Authors
Ritmeijer, Koertter Horst, Rachel
Chane, Solomon
Aderie, Endashaw Mengistu
Piening, Turid
Collin, Simon M
Davidson, Robert N
Affiliation
Public Health Department, Médecins Sans Frontières, Amsterdam, the Netherlands. koert.ritmeijer@amsterdam.msf.orgIssue Date
2011-12
Metadata
Show full item recordJournal
Clinical Infectious Diseases : an official publication of the Infectious Diseases Society of AmericaAbstract
Due to unacceptably high mortality with pentavalent antimonials, Médecins Sans Frontières in 2006 began using liposomal amphotericin B (AmBisome) for visceral leishmaniasis (VL) patients in Ethiopia who were severely ill or positive for human immunodeficiency virus (HIV).PubMed ID
22016502Language
enISSN
1537-6591ae974a485f413a2113503eed53cd6c53
10.1093/cid/cir674